The global strand displacement amplification (SDA) market is projected to grow at a moderate pace through 2035, driven by increasing demand for rapid, sensitive, and cost-effective molecular diagnostic techniques. SDA is an isothermal nucleic acid amplification method used widely for pathogen detection, genetic screening, and point-of-care testing.
Its ability to amplify DNA at a constant temperature without the need for thermal cycling equipment makes it especially valuable in low-resource settings and decentralized diagnostic environments. In 2025, the global strand displacement amplification (SDA) market is estimated to be valued at approximately USD 1,631.7 Million. By 2035, it is projected to grow to around USD 2,392.2 Million, reflecting a compound annual growth rate (CAGR) of 3.9%.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 1,631.7 Million |
| Projected Market Size in 2035 | USD 2,392.2 Million |
| CAGR (2025 to 2035) | 3.9% |
With growing adoption in infectious disease diagnostics, food safety testing, and personalized medicine, the SDA market is expanding steadily. Ongoing innovations in portable diagnostic devices and integration with microfluidics and lab-on-a-chip platforms are further enhancing its market potential.
Explore FMI!
Book a free demo
North America is the most prominent market for SDA, with a significant presence of molecular diagnostics companies, considerable R&D investments, and extensive uses in infectious disease testing and genetic diagnostics. SDA-based assays are clinically adopted and commercially available in the USA.
Strong regulatory support, rising demand for molecular testing technologies, and the adoption of rapid diagnostic platforms are driving the SDA market growth in Europe. Expanded SDA applications in healthcare and food safety sectors by countries including Germany, the UK, and France.
SDA is the fastest-growing market in the Asia-Pacific region due to factors such as the increasing development of healthcare infrastructure, rising awareness of molecular diagnostics, and an increase in government funding for disease surveillance and diagnostics. China, India, and Japan lead new SDA test development in clinical and public health settings.
Technical Complexity, Limited Multiplexing, and Standardization Gaps
The strand displacement amplification (SDA) market are mainly due to the technical complexity of the method mainly in comparison to more popular and mainstream amplification technologies like PCR and LAMP. SDA uses extremely strictly designed primers, nicking endonucleases, and polymerases with strand displacement activity, which means that assay development and optimization is a labor-intensive, tough-to-multiplex process.
Additionally, the clinical adoption of assays is impeded by the absence of standardized or widely recognized assay validation parameters and regulatory frameworks in the market.
Minimizing cross-contamination risk and effective collection methods may help improve assay sensitivity and specificity for diverse targets essential for point-of-care or resource-limited diagnostics, particularly for low-abundance nucleic acids, but manufacturers also struggle with standardizing sensitivity and specificity for diverse targets.
Isothermal Amplification Demand, POC Diagnostics, and Infectious Disease Testing
Despite these limitationsthe SDA market offers ample growth opportunities that can be attributed to increasing demand of rapid, isothermal nucleic acid amplification technologies for point-of-care (POC) as well as field diagnostics and resource inadequate laboratories.
This isothermal nature of SDA also facilitates rapid amplification without thermal cycles, minimizing instrumentation complexity and supporting formats for point-of-care diagnostics. Additionally, it has been applied in early-stage infectious disease detection (e.g., TB, STDs and viral infections) and genetic testing, among others, adding value to decentralized healthcare ecosystems.
Moreover, the progress in microfluidics, chip-based detection and lyophilized reagent kits are allowing SDA-based integration into handheld diagnostic platforms and multiplex pathogen panels.
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Limited to RUO (research use only) and lab-developed tests (LDTs) in some countries. |
| Consumer Trends | Rising demand for low-cost, rapid genetic diagnostics in infectious disease testing. |
| Industry Adoption | Used in research labs, STI screening, and pathogen detection assays. |
| Supply Chain and Sourcing | Dependent on recombinant enzymes (polymerases, endonucleases) and synthetic primers. |
| Market Competition | Niche technology offered by molecular diagnostics startups and research reagent suppliers. |
| Market Growth Drivers | Supported by rise in STDs, TB screening needs, and antimicrobial resistance surveillance. |
| Sustainability and Environmental Impact | Focus on enzyme storage, plastic use in cartridges, and waste management. |
| Integration of Smart Technologies | Initial deployment in lab-based assays and benchtop POC analyzers. |
| Advancements in Amplification Chemistry | Basic SDA protocols used in single-target infectious disease tests. |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Broader IVD (in-vitro diagnostics) approvals, point-of-care assay guidelines, and clinical performance benchmarks. |
| Consumer Trends | Surge in decentralized genetic testing, telemedicine-linked diagnostics, and wearable DNA sensors. |
| Industry Adoption | Expansion into clinical diagnostics, home testing kits, and rapid response healthcare infrastructure. |
| Supply Chain and Sourcing | Shift toward ready-to-use reagent cartridges, lyophilized SDA kits, and local biomanufacturing hubs. |
| Market Competition | Entry of POC device innovators, healthcare diagnostics firms, and AI-integrated platform developers. |
| Market Growth Drivers | Driven by portable genomics, epidemic preparedness, and personalized diagnostic devices. |
| Sustainability and Environmental Impact | Movement toward biodegradable diagnostic kits, recyclable chip-based formats, and energy-efficient devices. |
| Integration of Smart Technologies | Growth of AI-guided assay optimization, cloud-based result integration, and mobile-phone interfacing. |
| Advancements in Amplification Chemistry | Development of multiplexed, rapid-turnaround SDA platforms for syndromic testing and portable screening. |
The USA Strand Displacement Amplification (SDA) market is growing at a steady pace, supported by the increasing adoption of isothermal nucleic acid amplification technologies for infectious disease diagnostics, food safety testing, and biodefense applications. SDA is especially useful because it allows for fast amplification at low temperatures, enabling point-of-care and field diagnostics, especially in rural and decentralized health care environments.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 4.0% |
SDA market in the United Kingdom is growing at a high pace, owing to the increasing use of molecular diagnostics in public health labs, rising research in antimicrobial resistance (AMR), and growing focus on rapid, low-complexity platforms. Moreover, SDA-based assays are receiving increasing attention for cost-time-effective diagnosis of both bacterial and viral infections in clinical and veterinary fields.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 3.8% |
Across the EU, SDA market stakeholders benefitted from key investments in rapid molecular diagnostic tools, zoonotic disease surveillance, and decentralized testing efforts underpinned by overarching one health programmers. Because rapid results are especially important, SDA is making its way into clinical microbiology and food contamination screening in countries including Germany and France.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union (EU) | 3.9% |
Japanese market is moderately growing, majorly driven by advance research and development in molecular biology, upsurge in investment towards portable diagnostic technologies, and shift towards early detection of chronic and infectious diseases. SDA has become a part of low-throughput, rapid diagnostic kits used in hospitals and elderly care centers.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 3.8% |
The SDA market in South Korea is growing along with the biotech, with rising support of molecular diagnostics startups and the inclusion of SDA into smart diagnostic platforms. Environmental pathogen detection and agricultural bio surveillance is also being developed using the SDA approach.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 4.0% |
The strand displacement amplification (SDA) market is also witnessing a steady growth due to the increasing importance of molecular diagnostics as a critical instrument for the early detection of diseases, screening of infectious diseases, and genetic testing. SDA is an isothermal DNA amplification method that offers several advantages such as rapidity, simplicity, and specificity, which make it suitable for both laboratory and point-of-care applications.
With the increasing need for affordable and precise nucleic acid assessment, SDA is being implemented in public health programs as a potentially appropriate approach, particularly in resource-limited areas of the world. Market by Application (Tuberculosis, Hepatitis, Pneumonia, Malaria, Cancer) and End User (Research Institutes, Hospitals, Diagnostic Laboratories).
| Application | Market Share (2025) |
|---|---|
| Tuberculosis | 34.5% |
By 2025, tuberculosis (TB) segment is expected to dominate the soma detection agent (SDA) market with 34.5% share. Until today, TB remains a major threat to global health, and it is essential to have rapid, sensitive, and point-of-care diagnostics tools, especially for low- and middle-income countries. The amplification of Mycobacterium tuberculosis DNA in a less than 20 min, even in low level of bacterial load, without sequence proving, resulting in early diagnosis and treatment.
With WHO detection targets in sight, global TB control programs are investing in molecular diagnostics, and SDA can provide a lower-cost alternative to PCR, with the additional advantage of no thermal cycling needs. Its utility in both community health and mobile testing work has made it especially valuable.
| End User | Market Share (2025) |
|---|---|
| Diagnostic Laboratories | 42.1% |
Although they are not primarily used as routine diagnostics, the majority of SDA-based assays (42.1% share of the market by 2025) will continue being used at diagnostic laboratories. These laboratories also process high volumes of testing, relying on robust, scalable, and rapid molecular platforms for processing clinical samples across infectious disease panels.
SDA has also been integrated into automated testing platforms and even point-of-care diagnostics to allow labs to provide faster turnaround while maintaining the accuracy and sensitivity. SDA has critical role in routine detection of bacterial and viral pathogens as public and private sector labs develop their molecular testing capacity, as was the case with the recent global public health crisis.
The Strand Displacement Amplification (SDA) market is projected to expand at a significant pace due to rise in demand for real-time and isothermal nucleic acid amplification in point-of-care diagnostics, infectious disease testing, and genetic screening.
By utilizing isothermic conditions, SDA allows for rapid DNA amplification without the need for significant equipment, and is well suited for resource-limited settings and the real-time identification of pathogens. The latest trends from market leaders are compact device integration, multiplexing, and low-cost disposable platforms for decentralized testing.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Becton, Dickinson and Company (BD) | 20-24% |
| Hologic, Inc. | 16-20% |
| New England Biolabs, Inc. | 12-16% |
| Meridian Bioscience, Inc. | 8-12% |
| QuidelOrtho Corporation | 6-9% |
| Other Companies (combined) | 20-25% |
| Company Name | Key Offerings/Activities |
|---|---|
| BD (Becton, Dickinson) | In 2024, enhanced its BD MAX™ platform with SDA-based assays for multi-pathogen respiratory panels. In 2025, launched disposable SDA cartridge systems for decentralized infectious disease testing. |
| Hologic, Inc. | In 2024, upgraded Panther Fusion® assays using SDA chemistry for HPV and STI diagnostics. In 2025, developed multiplex SDA test kits with reduced turnaround times for women’s health screening. |
| New England Biolabs (NEB) | In 2024, released standalone SDA enzyme kits for research and low-resource lab use. In 2025, expanded offerings to include lyophilized reagent kits for portable genetic detection. |
| Meridian Bioscience | In 2024, introduced SDA-compatible isothermal amplification kits for respiratory and GI pathogens. In 2025, partnered with diagnostics startups to create cost-effective, field-ready SDA test platforms. |
| QuidelOrtho Corporation | In 2024, adapted its Savanna® system for SDA-driven diagnostics targeting influenza and RSV. In 2025, launched dual SDA + LAMP hybrid formats for increased detection accuracy in POCT environments. |
Key Company Insights
BD (20-24%)
BD leads the market with automated SDA-based diagnostic systems that support syndromic testing and rapid disease surveillance. Its focus on compact test formats and integrated sample-to-answer solutions drives adoption across clinical and near-patient settings.
Hologic, Inc. (16-20%)
Hologic uses SDA as a core amplification technology in its Panther® assay suite, providing high-throughput, molecular diagnostics for sexual health, viral load testing, and women's health programs.
New England Biolabs (12-16%)
NEB supports academic, clinical, and research institutions with enzyme kits, buffers, and reagent-grade SDA systems, emphasizing flexibility, customization, and low-infrastructure deployment.
Meridian Bioscience (8-12%)
Meridian offers easy-to-use SDA kits for diagnostic OEMs and public health labs, with growing adoption in respiratory, gastrointestinal, and foodborne pathogen detection.
QuidelOrtho (6-9%)
QuidelOrtho is innovating at the intersection of SDA and other isothermal techniques, offering portable systems with short processing times, especially suited for emergency and urgent care diagnostics.
Other Key Players (20-25% Combined)
The overall market size for the strand displacement amplification (SDA) market was USD 1,631.7 Million in 2025.
The strand displacement amplification (SDA) market is expected to reach USD 2,392.2 Million in 2035.
Growth is driven by the increasing need for rapid and sensitive nucleic acid detection, rising adoption in infectious disease diagnostics and molecular research, and advancements in isothermal amplification technologies that enable point-of-care testing.
The top 5 countries driving the development of the strand displacement amplification market are the USA, China, Germany, Japan, and South Korea.
Tuberculosis Detection and Diagnostic Laboratories are expected to command a significant share over the assessment period.
CGRP Inhibitors Market Trends - Growth, Demand & Forecast 2025 to 2035
Indolent Systemic Mastocytosis treatment Market Insights: Size, Trends & Forecast 2025 to 2035
Intraoperative Fluorescence Imaging Market Report - Demand, Trends & Industry Forecast 2025 to 2035
Lung Cancer PCR Panel Market Trends, Growth, Demand & Forecast 2025 to 2035
Polymyxin Resistance Testing Market Analysis by Product, Testing Methods, End User, and Region - Forecast for 2025 to 2035
Procalcitonin (PCT) Assay Market Analysis by Component, Type, and Region - Forecast for 2025 to 2035
Strand Displacement Amplification (SDA) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
